

CELEBRATE PREDICTABILITY WITH EFFICIENT FERTILITY PRODUCTS.

Learn more at synctheherd.com



	GONADORELINS					PROSTAGLANDINS					
	CYSTORELIN®	Factrel®	Fertagyl®	GONAbreed®	OvaCyst™	SYNCHSURE®	Lutalyse®	LUTALYSE® HighCon	Estrumate®	estroPLAN®	ProstaMate®
Active Ingredient	Gonadorelin diacetate tetrahydrate	Gonadorelin hydrochloride	Gonadorelin acetate	Gonadorelin acetate	Gonadorelin diacetate tetrahydrate	Cloprostenol sodium	Dinoprost tromethamine	Dinoprost tromethamine	Cloprostenol sodium	Cloprostenol sodium	Dinoprost tromethamine
Storage Temperature	At or below 77°F	Refrigerate 36° to 46°F	Refrigerate 36°-46°F	Refrigerate 36°-46°F	68°-77°F	68°-77°F	68°-77°F	77°F	36°-86°F	68°-77°F	68°-77°F
Shelf Life	6 months	1 month	28-day use	180-day use	3 months	180-day use	12-week use	12-week use	28-day use	180-day use	3 months
Dosage	2 mL	2-4 mL	2 mL	1 mL	2 mL	2 mL	5 mL	2 mL	2 mL	2 mL	5 mL
Routes of Administration	IM or IV	IM	IM or IV	IM or IV	IM or IV	IM	IM	IM or SC	IM	IM	IM

CYSTORELIN IMPORTANT SAFETY INFORMATION: Do not use in humans. Keep this and all drugs out of the reach of children.

SYNCHSURE IMPORTANT SAFETY INFORMATION: For animal use only, not for human use. Keep out of reach of children. Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. SYNCHSURE (cloprostenol sodium) is readily absorbed through the skin and may cause abortion and/or bronchospasms; direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

CYSTORELIN®

(gonadorelin)

50mcg/mL gonadorelin diacetate tetrahydrate Injectable Solution

For treatment of cystic ovaries in dairy cattle

For use with cloprostenol sodium to synchronize estrous cycles to allow for fixed time artificial insemination (FTAI) in lactating dairy cows and beef cows.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

CYSTORELIN® (gonadorelin) is a sterile solution containing 43 mcg/mL of gonadorelin (GnRH) as 50 mcg/mL gonadorelin diacetate tetrahydrate suitable for intramuscular or intravenous administration according to the indication. Gonadorelin is a decapeptide composed of the sequence of amino acids—

5-oxoPro-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2—
a molecular weight of 1182.32 and empirical formula C₅₅H₇₃N₁₇O₁₃. The diacetate tetrahydrate ester has a molecular weight of 1374.48 and empirical formula C₅₉H₈₁N₁₇O₂₁.
Each mL of CYSTORELIN contains:

Gonadorelin diacetate tetrahydrate (equivalent to 43 mcg gonadorelin).....	50 mcg
Benzyl Alcohol	9 mg
Sodium Chloride	7.47 mg
Water for Injection.....	q.s.

pH adjusted with potassium phosphate (monobasic and dibasic).

Gonadorelin is the hypothalamic releasing factor responsible for the release of gonadotropins (e.g., luteinizing hormone [LH], follicle stimulating hormone [FSH]) from the anterior pituitary. Synthetic gonadorelin is physiologically and chemically identical to the endogenous bovine hypothalamic releasing factor.

INDICATIONS FOR USE:

Cystic Ovaries

CYSTORELIN is indicated for the treatment of ovarian follicular cysts in dairy cattle. Ovarian cysts are non-ovulated follicles with incomplete luteinization which result in nymphomania or irregular estrus. Historically, cystic ovaries have responded to an exogenous source of LH such as human chorionic gonadotrophin. CYSTORELIN initiates release of endogenous LH to cause ovulation and luteinization.

Reproductive Synchrony

CYSTORELIN is indicated for use with cloprostenol sodium to synchronize estrous cycles to allow for fixed time artificial insemination (FTAI) in lactating dairy cows and beef cows.

DOSAGE AND ADMINISTRATION:

Cystic Ovaries

The intravenous or intramuscular dosage of CYSTORELIN is 100 mcg gonadorelin diacetate tetrahydrate (2 mL) per cow.

Reproductive Synchrony

The intramuscular dosage of CYSTORELIN is 100 mcg gonadorelin diacetate tetrahydrate (2 mL) per cow, used in reproductive synchrony programs similar to the following:

1. Administer the first CYSTORELIN injection (2 mL) at Time 0.
2. Administer 500 mcg cloprostenol (as cloprostenol sodium) by intramuscular injection 6 to 8 days after the first CYSTORELIN injection.
3. Administer the second CYSTORELIN injection (2 mL) 30 to 72 hours after the cloprostenol sodium injection.
4. Perform FTAI 0 to 24 hours after the second CYSTORELIN injection, or inseminate cows on detected estrus using standard herd practices.

WARNINGS AND PRECAUTIONS:

Not for use in humans.

Keep out of reach of children.

WITHDRAWAL PERIODS:

No withdrawal period or milk discard time is required when used according to the labeling.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Boehringer Ingelheim Animal Health USA Inc. 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or www.fda.gov/reportanimalae.

PHARMACOLOGY AND TOXICOLOGY:

Endogenous gonadorelin is synthesized and/or released from the hypothalamus during various stages of the bovine estrus cycle following appropriate neurogenic stimuli. It passes via the hypophyseal portal vessels, to the anterior pituitary to effect the release of gonadotropins (e.g., LH, FSH). Synthetic gonadorelin administered intravenously or intramuscularly also causes the release of endogenous LH or FSH from the anterior pituitary. Gonadorelin diacetate tetrahydrate has been shown to be safe. The LD50 for mice and rats is greater than 60 mg/kg, and for dogs, greater than 600 mcg/kg, respectively. No adverse effects were noted among rats or dogs administered 120 mcg/kg/day or 72 mcg/kg/day intravenously for 15 days.

It had no adverse effects on heart rate, blood pressure, or EKG to unanesthetized dogs at 60 mcg/kg. In anesthetized dogs it did not produce depression of myocardial or system hemodynamics or adversely affect coronary oxygen supply or myocardial oxygen requirements.

The intravenous administration of 60 mcg/kg/day of gonadorelin diacetate tetrahydrate to pregnant rats and rabbits during organogenesis did not cause embryotoxic or teratogenic effects. Further, CYSTORELIN did not cause irritation at the site of intramuscular administration in dogs with a dose of 72 mcg/kg/day administered for seven (7) days.

TARGET ANIMAL SAFETY:

In addition to the animal safety information presented in the PHARMACOLOGY AND TOXICOLOGY section, the safety of CYSTORELIN was established through the review and evaluation of the extensive published literature available for the use of gonadorelin-containing products.

The intramuscular administration of 1000 mcg gonadorelin diacetate tetrahydrate on five (5) consecutive days to normally cycling dairy cattle had no effect on hematology or clinical chemistries.

In field studies evaluating the effectiveness of CYSTORELIN for the treatment of ovarian follicular cysts, the incidence of health abnormalities was not significantly greater in cows administered CYSTORELIN than cows administered a placebo injection.

The target animal safety of, and injection site reactions to, gonadorelin when used with cloprostenol sodium were evaluated during the conduct of effectiveness field studies. The incidence of health abnormalities was not significantly greater in cows administered gonadorelin than cows administered a placebo injection.

EFFECTIVENESS:

The use of CYSTORELIN for treatment of ovarian follicular cysts in dairy cattle was demonstrated to be effective with a treatment dose of 100 mcg gonadorelin diacetate tetrahydrate. The effectiveness of gonadorelin for use with cloprostenol sodium to synchronize estrous cycles to allow for FTAI in lactating dairy cows was demonstrated in a field study at 10 different locations in the U.S. Four of the locations represented conditions that would typically cause heat stress in lactating cows. A total of 1607 healthy, non-pregnant, primiparous or multiparous lactating dairy cows within 40-150 days postpartum were enrolled in the study. A total of 805 cows were administered gonadorelin (1 mL; 100 mcg gonadorelin as the acetate salt) and 802 cows were administered an equivalent volume of water for injection as an intramuscular injection twice in the following regimen:

Day 0: 100mcg gonadorelin (as the acetate salt) or sterile water for injection

Day 7: 500 mcg cloprostenol (as cloprostenol sodium)

Day 9: 100mcg gonadorelin (as the acetate salt) or sterile water for injection

Fixed time AI was performed on Day 10, approximately 11 - 31 hours after the Day 9 injection. Cows were evaluated for pregnancy on Day 45 ± 5 days by trans-rectal ultrasound or rectal palpation. Pregnancy rate to FTAI was significantly higher (P < 0.0001) in cows treated with gonadorelin (33.4%) than the pregnancy rate to FTAI in cows treated with water (13.6%). The environmental condition (heat stress or not heat stress) did not affect the conclusion of effectiveness. The effectiveness of gonadorelin for use with cloprostenol sodium to synchronize estrous cycles to allow for FTAI in beef cows was demonstrated in a field study at 10 different locations in the U.S. A total of 706 healthy, non-pregnant, primiparous or multiparous beef cows within 40-150 days postpartum were enrolled in the study. A total of 364 cows were administered gonadorelin (1 mL; 100 mcg gonadorelin as the acetate salt) and 342 cows were administered an equivalent volume of water for injection as an intramuscular injection twice in the following regimen:

Day 0: 100mcg gonadorelin (as the acetate salt) or sterile water for injection

Day 7: 500 mcg cloprostenol (as cloprostenol sodium)

Day 9: 100mcg gonadorelin (as the acetate salt) or sterile water for injection

Fixed time AI was performed immediately after the Day 9 injection. Cows were evaluated for pregnancy on Day 55 ± 5 days by trans-rectal ultrasound. Pregnancy rate to FTAI was significantly higher (P = 0.0006) in cows treated with gonadorelin (21.7%) than the pregnancy rate to FTAI in cows treated with water (7.4%).

The effectiveness of a 2-mL dose of CYSTORELIN delivering 100 mcg gonadorelin diacetate tetrahydrate (86 mcg gonadorelin) for use with cloprostenol sodium to synchronize estrous cycles to allow for FTAI in lactating dairy cows and beef cows was also demonstrated through references to scientific literature.

HOW SUPPLIED:

CYSTORELIN is available in a concentration of 50 mcg/mL gonadorelin diacetate tetrahydrate (43 mcg/mL gonadorelin) pH adjusted with potassium phosphate (monobasic and dibasic).

CYSTORELIN is supplied in multi-dose vials containing 10mL, 30mL, 50mL, and 100mL of sterile solution.

STORAGE, HANDLING, AND DISPOSAL: Store at or below 77°F (25°C). Brief excursions to 86°F (30°C) are permitted. Use within 6 months of first puncture.

1050-2907-05 Rev. 08/2019

Approved by FDA under NADA#098-379

Made in Australia.

Marketed by: Boehringer Ingelheim Animal Health USA Inc., Duluth, GA 30096

CYSTORELIN® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.
©2022 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0583-2022



SYNCHSURE®

(cloprostenol sodium)

Prostaglandin Analogue for Cattle

Equivalent to 250 mcg cloprostenol/mL

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION:

SYNCHSURE® (cloprostenol sodium) is a synthetic prostaglandin analogue structurally related to prostaglandin F_{3α} (PGF_{3α}). Each mL of the colorless aqueous solution contains 263 mcg of cloprostenol sodium (equivalent to 250 mcg of cloprostenol), chlorocresol 1.0 mg as a bactericide, citric acid anhydrous 0.66 mg, sodium citrate 5.03 mg, sodium chloride 6.76 mg. The pH is adjusted, as necessary, with sodium hydroxide or citric acid.

ACTION: SYNCHSURE causes functional and morphological regression of the *corpus luteum* (luteolysis) in cattle. In normal, nonpregnant cycling animals, this effect on the life span of the corpus luteum usually results in estrus 2 to 5 days after treatment. In animals with prolonged luteal function (pyometra, mummified fetus, and luteal cysts), the induced luteolysis usually results in resolution of the condition and return to cyclicity. Pregnant animals may abort depending on the stage of gestation.

INDICATIONS: For intramuscular use to induce luteolysis in beef and dairy cattle. The luteolytic action of SYNCHSURE can be utilized to manipulate the estrous cycle to better fit certain management practices, to terminate pregnancies resulting from mismatings, and to treat certain conditions associated with prolonged luteal function.

RECOMMENDED USES:

Unobserved or Nondetected Estrus: Cows which are not detected in estrus, although ovarian cyclicity continues, can be treated with SYNCHSURE if a mature *corpus luteum* is present. Estrus is expected to occur 2 to 5 days following injection, at which time animals may be inseminated. Treated cattle should be inseminated at the usual time following detection of estrus. If estrus detection is not desirable or possible, treated animals may be inseminated twice at about 72 and 96 hours postinjection.

Pyometra or Chronic Endometritis: Damage to the reproductive tract at calving or postpartum retention of the placenta often leads to infection and inflammation of the uterus (endometritis). Under certain circumstances, this may progress into chronic endometritis with the uterus becoming distended with purulent matter. This condition, commonly referred to as pyometra, is characterized by a lack of cyclical estrus behavior and the presence of a persistent *corpus luteum*. Induction of luteolysis with SYNCHSURE usually results in evacuation of the uterus and a return to normal cyclical activity within 14 days after treatment. After 14 days posttreatment, recovery rate of treated animals will not be different than that of untreated cattle.

Mummified fetus: Death of the conceptus during gestation may be followed by its degeneration and dehydration. Induction of luteolysis with SYNCHSURE usually results in expulsion of the mummified fetus from the uterus. (Manual assistance may be necessary to remove the fetus from the vagina). Normal cyclical activity usually follows.

Luteal Cysts: A cow may be noncyclic due to the presence of a luteal cyst (a single, anovulatory follicle with a thickened wall which is accompanied by no external signs and by no changes in palpable consistency of the uterus). Treatment with SYNCHSURE can restore normal ovarian activity by causing regression of the luteal cyst.

Pregnancies from mismating: Unwanted pregnancies can be safely and efficiently terminated from 1 week after mating until about 5 months of gestation. The induced abortion is normally uncomplicated and the fetus and placenta are usually expelled about 4 to 5 days after the injection with the reproductive tract returning to normal soon after the abortion. The ability of SYNCHSURE to induce abortion decreases beyond the fifth month of gestation while the risk of dystocia and its consequences increases. SYNCHSURE has not been sufficiently tested under feedlot conditions; therefore recommendations cannot be made for its use in heifers placed in feedlots.

Controlled Breeding: The luteolytic action of SYNCHSURE can be utilized to schedule estrus and ovulation for an individual cycling animal or a group of animals. This allows control of the time at which cycling cows or heifers can be bred. SYNCHSURE can be incorporated into a controlled breeding program by the following methods:

1. Single SYNCHSURE Injection

2. Double SYNCHSURE Injections.

The use information provided here is not comprehensive. Talk to your veterinarian and consult the full prescribing information for further details on uses of SYNCHSURE.

SAFETY AND TOXICITY: At 50 and 100 times the recommended dose, mild side effects may be detected in some cattle. These include increased uneasiness, slight frothing, and milk let-down.

CONTRAINDICATIONS: SYNCHSURE should not be administered to a pregnant animal whose calf is not to be aborted.

WARNINGS: For animal use only. Women of childbearing age, asthmatics, and persons with bronchial and other respiratory problems should exercise extreme caution when handling this product. In the early stages, women may be unaware of their pregnancies. SYNCHSURE is readily absorbed through the skin and may cause abortion and/or bronchospasms; direct contact with the skin should therefore be avoided. Accidental spillage on the skin should be washed off immediately with soap and water.

PRECAUTIONS: There is no effect on fertility following the single or double dosage regimen when breeding occurs at induced estrus or at 72 and 96 hours posttreatment. Conception rates may be lower than expected in those fixed time breeding programs which omit the second insemination (i.e. the insemination at or near 96 hours). This is especially true if a fixed time insemination is used following a single SYNCHSURE injection.

As with all parenteral products, careful aseptic techniques should be employed to decrease the possibility of postinjection bacterial infection. Antibiotic therapy should be employed at the first sign of infection.

The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information. To obtain an MSDS or for technical assistance, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. To report suspected adverse drug experiences, contact Boehringer Ingelheim Animal Health USA Inc. at 1-888-637-4251. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or <http://www.fda.gov/reportanimalae>.

DOSAGE AND ADMINISTRATION: Two mL of SYNCHSURE (500 mcg of cloprostenol) should be administered by INTRAMUSCULAR INJECTION for all indications in both beef and dairy cattle. Discard remaining product 180 days after first use.

STORAGE CONDITIONS:

1. Protect from light.
2. Store in carton.
3. Store at controlled room temperature 20°-25°C (68°-77°F).

HOW SUPPLIED: 100mL multidose vial

1050-8918-01 Rev. 10-2020

Made in Australia

Distributed by:

Boehringer Ingelheim Animal Health USA Inc. Duluth, GA 30096

Approved by FDA under ANADA # 200-310

100 mL: 50331b-02

SYNCHSURE® is a registered trademark of Boehringer Ingelheim Animal Health USA Inc.
©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0584-2022-V2

